Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 5.4% year on year to $183.9 million. Its non-GAAP profit of $0.91 per share was 48.3% above analysts’ consensus estimates.

Is now the time to buy AMPH? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Amphastar Pharmaceuticals delivered results in Q2 that surpassed Wall Street expectations, reflecting continued strength across its diversified product portfolio and new product introductions. Management pointed to robust demand for commercial brands like BAQSIMI and Primatene MIST, as well as the successful launch of ipratropium bromide, as key drivers behind the quarter’s growth. CEO Bill Peters emphasized the company's progress in expanding manufacturing capabilities and advancing its development pipeline, noting, “We observed continued demand across our commercial portfolio and expanded our manufacturing capabilities.” The positive market reaction followed management’s focus on execution despite ongoing pricing dynamics and competitive pressures in select product lines.

Looking ahead, Amphastar’s guidance is shaped by ongoing investments in its proprietary product pipeline, further manufacturing expansion, and the remediation of its IMS facility following a recent FDA warning letter. Management highlighted plans to support growth through the commercialization of pipeline candidates and a disciplined approach to spending. CFO Bill Peters stated, “We are focused on supporting continued growth across our commercial portfolio, expanding our U.S. manufacturing capabilities, and advancing our near-term regulatory programs.” The company anticipates stable sales growth and margin performance, while navigating potential cost increases and operational adjustments at IMS.

Key Insights from Management’s Remarks

Management attributed Q2’s outperformance to increased prescription volumes in key brands, new product launches, and disciplined portfolio diversification. Investments in manufacturing and regulatory progress also played a substantial role.

• BAQSIMI prescription growth: While BAQSIMI’s net sales declined due to pricing and rebate pressures, total prescriptions rose 17% year-over-year, highlighting sustained patient demand and reinforcing management’s confidence in this diabetes-related brand’s long-term trajectory.
• Primatene MIST resilience: Primatene MIST continued to see strong consumer demand and improved in-store sales, with management noting that net sales declines were due to temporary shipment and retailer inventory timing—not underlying market weakness.
• Ipratropium bromide launch: The recent introduction of this inhalation product highlighted Amphastar’s ability to bring complex generic drugs to market. Management described early demand as robust and sees this as a new, higher-margin revenue stream.
• IMS facility FDA warning letter: Remediation at the IMS manufacturing site will require additional resources and may temporarily slow sales from the facility, but management does not anticipate a material adverse effect on the overall business. Steps have been taken to address quality concerns and maintain production continuity.
• Pipeline advancement: Amphastar achieved key milestones in its proprietary and biosimilar pipeline, including initiating Phase I trials for AMP-101 (epinephrine nasal) and progressing towards regulatory submissions for insulin aspart and other candidates in oncology and ophthalmology.

Drivers of Future Performance

Amphastar’s forward outlook is anchored by continued product diversification, manufacturing investments, and the execution of its development pipeline, though cost headwinds and regulatory remediation remain key themes.

• Manufacturing and remediation costs: The company expects higher operating expenses over the next few quarters, largely from remediation activities at the IMS facility. Management indicated that these costs will be offset by redirection of capital spending from other sites, but investors should expect a moderate impact on operating margins.
• Pipeline commercialization: Management is focused on advancing late-stage candidates such as the insulin aspart biosimilar, targeting commercialization in 2027. Success here would broaden Amphastar’s market exposure and reduce reliance on existing brands.
• Portfolio resilience amid competition: While products like glucagon face ongoing competitive pressure, management expects the impact of new launches and stable demand for core brands to support mid- to high-single-digit sales growth. Risks include pricing dynamics and the outcome of regulatory reviews.

Catalysts in Upcoming Quarters

In upcoming quarters, the StockStory team will monitor (1) execution of IMS facility remediation and any related operational disruptions, (2) progress on pipeline milestones such as regulatory filings and new clinical trial initiations, and (3) continued uptake for newly launched products like ipratropium bromide. Additionally, shifts in pricing dynamics for core brands and the impact of manufacturing investments will be important signposts for Amphastar’s execution.

Amphastar Pharmaceuticals currently trades at $21.84, up from $19.81 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.